14 February 2024
14 February 2024
Two FDA representatives FDA spoke at the ongoing 2024 SCOPE Summit about how the agency is focusing on AI.
Grifols’s Phase III AdFIrst trial met its primary endpoint.
The company is initially focusing on developing alisertib for small-cell lung cancer and breast cancer.
The trial will assess the safety and tolerability of OLX75016 in a randomised, double-blind, placebo-controlled setting.
The study is due to begin in the first half of this year, with data readout expected next year.
The trial of sebetralstat met all its primary and secondary endpoints.
The biotech believes cyclisation of its candidate gives it an advantage over already marketed mitogen-activated protein kinase (MEK) inhibitors.
LDL-C reduction was observed in 43.3% of patients dosed every two weeks and 33.8% in patients dosed every four weeks.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
